SCHEMBL29699370

SCHEMBL29699370

Clc1ccc(Sc2c[nH]nn2)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HAO1 Q9UJM8 1/20 0.53
NOTUM Q6P988 1/20 0.43
LMNA P02545 3/20 0.42
MAPT P10636 1/20 0.42
RECQL P46063 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GRM5 P41594 4/20 0.40
AKT1 P31749 1/20 0.37
MAPK13 O15264 1/20 0.35
MAPK12 P53778 1/20 0.35
MAPK11 Q15759 1/20 0.35
MAPK14 Q16539 1/20 0.35
HTR1A P08908 1/20 0.35
HTR3A P46098 1/20 0.35
TP53 P04637 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
FBP1 P09467 1/20 0.34
ALDH1A1 P00352 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23458008 0.87 AHR (0.42) HAO1NOTUMLMNAMAPTRECQL
SCHEMBL29699607 0.87 AHR (0.42) HAO1NOTUMLMNAMAPTRECQL
SCHEMBL23457570 0.82 ALDH1A1 (0.38) HAO1LMNAMAPK14MEN1KMT2A
SCHEMBL29699478 0.81 LMNA (0.40) HAO1LMNAMAPTTP53ALDH1A1
SCHEMBL23457595 0.81 LMNA (0.40) HAO1LMNAMAPTTP53ALDH1A1
SCHEMBL23457507 0.77 HAO1 (0.43) HAO1NOTUMLMNAMAPTTDP1
SCHEMBL29699408 0.76 NOTUM (0.43) HAO1NOTUMGRM5TYMS
SCHEMBL23457559 0.75 MARS1 (0.42) LMNAMAPTMAPK14TP53ALDH1A1
SCHEMBL23457612 0.72 NPC1 (0.32) MAPTTP53MEN1KMT2AALDH1A1
SCHEMBL23457573 0.72 DAO (0.39) HAO1NOTUMMAPTTDP1FBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 US disclosed
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 US disclosed
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-16 US disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT HAO1 9/4885NOTUM 643/4885LMNA 2434/4885
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT HAO1 10/4885NOTUM 602/4885LMNA 2638/4885
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT HAO1 9/4885NOTUM 643/4885LMNA 2434/4885
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT HAO1 9/4885NOTUM 643/4885LMNA 2434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.